Betamethasone Valerate Lotion
If you find any inaccurate information, please let us know by providing your feedback here

This article is compiled based on the United States Pharmacopeia (USP) – 2025 Edition
Issued and maintained by the United States Pharmacopeial Convention (USP)
1 DEFINITION
Betamethasone Valerate Lotion contains an amount of betamethasone valerate (C₂₇H₃₇FO₆) equivalent to NLT 95.0% and NMT 115.0% of the labeled amount of betamethasone (C₂₂H₂₉FO₅).
2 IDENTIFICATION
A. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.
B. The UV spectrum of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.
3 ASSAY
Procedure
Solution A: Water
Solution B: Acetonitrile
Mobile phase: See Table 1.
| Time (min) | Solution A (%) | Solution B (%) |
| 0.0 | 63 | 37 |
| 7.0 | 63 | 37 |
| 15.0 | 30 | 70 |
| 19.0 | 30 | 70 |
| 19.1 | 10 | 90 |
| 21.0 | 10 | 90 |
| 21.1 | 63 | 37 |
| 25.0 | 63 | 37 |
Diluent: Acetonitrile and water (40:60)
System suitability solution: 0.05 mg/mL of USP Betamethasone Valerate RS and 0.01 mg/mL of USP Betamethasone Valerate Related Compound A RS in Diluent. Sonicate to dissolve if necessary.
Standard solution: 0.05 mg/mL of USP Betamethasone Valerate RS in Diluent. Sonicate to dissolve if necessary.
Sample solution: Nominally 0.04 mg/mL of betamethasone in Diluent, prepared as follows. Accurately weigh and transfer a portion of Lotion to a suitable volumetric flask. Add about 80% of the final flask volume of Diluent. Sonicate for about 5 min. Dilute with Diluent to volume. Pass through a suitable filter of 0.2-µm pore size.
Chromatographic system
(See Chromatography 〈621〉, System Suitability.)
Mode: LC
Detector: UV 240 nm. For Identification B, use a diode array detector in the range of 200–400 nm.
Column: 4.6-mm × 15-cm; 3.5-µm packing L1
Temperatures
Column: Ambient
Autosampler: 4°
Flow rate: 1 mL/min
Injection volume: 50 µL
System suitability
Samples: System suitability solution and Standard solution
[Note—See Table 2 for relative retention times.]
Suitability requirements
Resolution: NLT 2.0 between betamethasone valerate and betamethasone valerate related compound A, System suitability solution
Tailing factor: NMT 2.0, Standard solution
Relative standard deviation: NMT 1.0%, Standard solution
Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of the labeled amount of betamethasone (C₂₂H₂₉FO₅) in the portion of Lotion taken:
Result = (r₁/r₂) × (C₁/C₂) × (M₁/M₂) × 100
r₁ = peak response from the Sample solution
r₂ = peak response from the Standard solution
C₁ = concentration of USP Betamethasone Valerate RS in the Standard solution (mg/mL)
C₂ = nominal concentration of betamethasone in the Sample solution (mg/mL)
M₁ = molecular weight of betamethasone, 392.46
M₂ = molecular weight of betamethasone valerate, 476.58
Acceptance criteria: 95.0%–115.0%
4 IMPURITIES
Organic Impurities
Solution A, Solution B, Mobile phase, Diluent, System suitability solution, Sample solution, and Chromatographic system: Proceed as directed in the Assay.
Standard solution: 0.001 mg/mL each of USP Betamethasone RS, USP Betamethasone Valerate RS, and USP Betamethasone Valerate Related Compound A RS in Diluent. Sonicate to dissolve if necessary.
System suitability
Samples: System suitability solution and Standard solution
[Note—See Table 2 for relative retention times.]
Suitability requirements
Resolution: NLT 2.0 between betamethasone valerate and betamethasone valerate related compound A, System suitability solution
Relative standard deviation: NMT 5.0%, Standard solution
Analysis
Samples: Sample solution and Standard solution
Calculate the percentage of each specified degradation product in the portion of Lotion taken:
Result = (r₁/r₂) × (C₁/C₂) × 100
r₁ = peak response of each specified degradation product from the Sample solution
r₂ = peak response of the corresponding USP Reference Standard from the Standard solution
C₁ = concentration of the corresponding USP Reference Standard in the Standard solution (mg/mL)
C₂ = nominal concentration of betamethasone in the Sample solution (mg/mL)
Calculate the percentage of each unspecified degradation product in the portion of Lotion taken:
Result = (r₁/r₂) × (C₁/C₂) × (M₁/M₂) × 100
r₁ = peak response of each unspecified degradation product from the Sample solution
r₂ = peak response of betamethasone valerate from the Standard solution
C₁ = concentration of USP Betamethasone Valerate RS in the Standard solution (mg/mL)
C₂ = nominal concentration of betamethasone in the Sample solution (mg/mL)
M₁ = molecular weight of betamethasone, 392.46
M₂ = molecular weight of betamethasone valerate, 476.58
Acceptance criteria: See Table 2. Disregard any impurity peak less than 0.1%.
| Name | Relative Retention Time | Acceptance Criteria, NMT (%) |
| Betamethasone | 0.30 | 1.0 |
| Betamethasone valerate | 1.00 | — |
| Betamethasone valerate related compound A | 1.04 | 10.0 |
| Any individual unspecified degradation product | — | 1.0 |
| Total degradation products | — | 12.0 |
5 SPECIFIC TESTS
Microbial Enumeration Tests 〈61〉 and Tests for Specified Microorganisms 〈62〉: Meets the requirements of the tests for absence of Staphylococcus aureus and Pseudomonas aeruginosa.
Minimum Fill 〈755〉: Meets the requirements
pH 〈791〉: 4.0–6.0
6 ADDITIONAL REQUIREMENTS
Packaging and Storage: Preserve in tight, light-resistant containers, and store at controlled room temperature.
USP Reference Standards 〈11〉
USP Betamethasone RS
USP Betamethasone Valerate RS
USP Betamethasone Valerate Related Compound A RS
9-Fluoro-11β,17-dihydroxy-16β-methyl-3,20-dioxopregna-1,4-dien-21-yl valerate.
C₂₇H₃₇FO₆ 476.58

